Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 181 participants.
Also called NCT06221059
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 181 participants
- Registry
-
NCT06221059
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06221059. Randomized; triple masking; primary purpose treatment. Start 2024-03-02 (actual); primary completion 2025-03-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- HRS-1780 tablet;Henagliflozin Proline tablet;HRS-1780 tablet placebo ;Henagliflozin Proline tablet placebo
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct06221059- Content hash
cbd7f4af72dacef3379edc3a8972f968f9a34effe8c5cb9227166b6edcb55588